R. Dummer

448 total citations
17 papers, 239 citations indexed

About

R. Dummer is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, R. Dummer has authored 17 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in R. Dummer's work include Cancer Immunotherapy and Biomarkers (7 papers), Melanoma and MAPK Pathways (6 papers) and CAR-T cell therapy research (5 papers). R. Dummer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Melanoma and MAPK Pathways (6 papers) and CAR-T cell therapy research (5 papers). R. Dummer collaborates with scholars based in Switzerland, Germany and Italy. R. Dummer's co-authors include Dirk Schadendorf, Paolo A. Ascierto, Ignacio Melero, Satyendra Suryawanshi, Kent Thudium, Christoph Höeller, Inge Marie Svane, Aurélien Marabelle, Shailender Bhatia and Carlos Gomez‐Roca and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

R. Dummer

17 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Dummer Switzerland 5 190 108 60 36 18 17 239
Mona Amini‐Adlé France 9 178 0.9× 48 0.4× 81 1.4× 25 0.7× 21 1.2× 30 275
Mirjam Fässler Switzerland 6 222 1.2× 104 1.0× 29 0.5× 45 1.3× 36 2.0× 7 282
Monirath Hav United States 8 102 0.5× 51 0.5× 57 0.9× 28 0.8× 29 1.6× 18 208
Kristen D. Felt United States 8 204 1.1× 71 0.7× 111 1.9× 72 2.0× 70 3.9× 23 306
Kazushige Koike Japan 5 165 0.9× 80 0.7× 49 0.8× 65 1.8× 8 0.4× 10 260
Laura Boullerot France 9 143 0.8× 162 1.5× 80 1.3× 32 0.9× 14 0.8× 17 260
Caleb Lampenfeld United States 4 176 0.9× 170 1.6× 61 1.0× 40 1.1× 9 0.5× 4 268
Alexander A. Girgis United States 4 111 0.6× 93 0.9× 59 1.0× 17 0.5× 11 0.6× 7 199
Marc Lucas Ooft Netherlands 6 295 1.6× 186 1.7× 102 1.7× 62 1.7× 21 1.2× 7 396
Haytham El Salhat Qatar 5 259 1.4× 267 2.5× 112 1.9× 31 0.9× 10 0.6× 7 398

Countries citing papers authored by R. Dummer

Since Specialization
Citations

This map shows the geographic impact of R. Dummer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Dummer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Dummer more than expected).

Fields of papers citing papers by R. Dummer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Dummer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Dummer. The network helps show where R. Dummer may publish in the future.

Co-authorship network of co-authors of R. Dummer

This figure shows the co-authorship network connecting the top 25 collaborators of R. Dummer. A scholar is included among the top collaborators of R. Dummer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Dummer. R. Dummer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Dimitriou, Florentia, J.C. Hassel, Marlana Orloff, et al.. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology. 33. S929–S929. 3 indexed citations
2.
3.
Ascierto, P.A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2022). LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation. Annals of Oncology. 33. S1408–S1409. 2 indexed citations
4.
Dummer, R., Nazima Pathan, Shibing Deng, et al.. (2022). 786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma. Annals of Oncology. 33. S902–S902. 2 indexed citations
5.
6.
Zaremba, Anne, Alexander M.M. Eggermont, Caroline Robert, et al.. (2021). The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. European Journal of Cancer. 155. 268–280. 45 indexed citations
7.
Mandalà, Mario, M. Del Vecchio, Helen Gogas, et al.. (2018). Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). British Journal of Cancer. 119(11). 41–42. 1 indexed citations
8.
9.
Koelblinger, Peter, Marjam J. Barysch, Joanna Mangana, et al.. (2018). The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma. Journal of the European Academy of Dermatology and Venereology. 33(4). 686–692. 16 indexed citations
10.
11.
Hauschild, Axel, Paul B. Chapman, Caroline Robert, et al.. (2016). Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study. Melanoma Research. 2 indexed citations
12.
Urosevic‐Maiwald, Mirjana, Simone M. Goldinger, A.L. Frauchiger, et al.. (2015). Efficacy and safety of oral alitretinoin in severe oral lichen planus – results of a prospective pilot study. Journal of the European Academy of Dermatology and Venereology. 30(2). 293–298. 18 indexed citations
13.
14.
Barysch, Marjam J., Maria B. Karpova, Hans C. Steinert, et al.. (2010). In vivo metabolic activity and transcriptional profiling in melanoma (MM) patients during sorafenib and dacarbazine (DTIC) treatment.. Journal of Clinical Oncology. 28(15_suppl). 8575–8575. 1 indexed citations
15.
Garbe, Claus, Axel Hauschild, R Linse, et al.. (2004). 22 Final results of two randomized adjuvant trials of DeCOG. Melanoma Research. 14(4). A10–A10. 1 indexed citations
16.
Dummer, R.. (2001). GVAX (Cell Genesys).. PubMed. 2(6). 844–8. 15 indexed citations
17.
Wussow, Peter von, et al.. (1997). Adjuvant Immunotherapy in Malignant Melanoma: Impact of Antibody Formation Against Interferon-?? on Immunoparameters In Vivo. Journal of Immunotherapy. 20(3). 208–209. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mona Amini‐Adlé Breakdown of academic impact, for papers by Mirjam Fässler Breakdown of academic impact, for papers by Monirath Hav Breakdown of academic impact, for papers by Kristen D. Felt Breakdown of academic impact, for papers by Kazushige Koike Breakdown of academic impact, for papers by Laura Boullerot Breakdown of academic impact, for papers by Caleb Lampenfeld Breakdown of academic impact, for papers by Alexander A. Girgis Breakdown of academic impact, for papers by Marc Lucas Ooft Breakdown of academic impact, for papers by Haytham El Salhat
Rankless by CCL
2026